

REMARKS

Claims 3, 5, 7, 8, 10, 13, 17, 22, 24, 26, 28, 30, 34, 38, 42, 46, 49 and 50 have been amended to clarify their meaning and to correct minor errors. No new matter has been added.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Carol A. Egner
Carol A. Egner
Registration No. 38,866
Telephone (781) 861-6240
Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: July 5, 2001

MARKED UP VERSION OF AMENDMENTS

3. (Amended) The method of Claim 2 wherein the substance is nerve growth factor, a biologically active fragment thereof or [the ligand is] a nerve growth factor pseudo-ligand that binds to the p75 nerve growth factor receptors.
5. (Amended) A method according to [claim 3] Claim 3 [where in] wherein the peptide is selected from the group consisting of SEQ ID NO: 4, 9 and 10.
7. (Amended) A method of Claim 6 comprising contacting epidermal keratinocytes with a substance, in an amount sufficient to inhibit cell loss, which binds to p75 nerve growth factor receptor expressed on the surface of the keratinocytes.
8. (Amended) The method of Claim 7 wherein the substance is nerve growth factor, a biologically active fragment thereof, or [the pseudo-ligand is] a nerve growth factor [pseudo-pseudo-ligand] pseudo-ligand that binds to the p75 nerve growth factor receptors.
10. (Amended) A method according to claim 9 [where in] wherein the peptide is selected from the group consisting of SEQ ID NO:4, 9 and 10.
13. (Amended) The method of Claim 12 wherein the substance is nerve growth factor, a biologically active fragment thereof or [the pseudo-ligand is] a nerve growth factor [pseudo-pseudo-ligand] pseudo-ligand that binds to the p75 nerve growth factor receptors.
17. (Amended) The method of Claim 16 wherein the substance is nerve growth factor, a biologically active fragment thereof [the pseudo-ligand is] or a nerve growth factor [pseudo-pseudo-ligand] pseudo-ligand that binds to the p75 nerve growth factor receptor.

22. (Amended) The method of Claim 21 wherein the substance is nerve growth factor, a biologically active fragment thereof or [the pseudo-ligand is] a nerve growth factor [pseudo-pseudo-ligand] pseudo-ligand that binds to the p75 nerve growth factor receptors.
24. (Amended) A method according to [claim 23] Claim 23 [where in] wherein the peptide is selected from the group consisting of SEQ ID NO:4, 9 and 10.
26. (Amended) The method of Claim 25 wherein the substance is nerve growth factor, a biologically active fragment thereof or [the pseudo-ligand is] a nerve growth factor [pseudo-pseudo-ligand] pseudo-ligand that binds to the p75 nerve growth factor receptors.
28. (Amended) A method according to [claim 27 where in] Claim 27 wherein the peptide is selected from the group consisting of SEQ ID NO: 4, 9 and 10.
30. (Amended) A method of Claim 29 wherein the pseudo-ligand is nerve growth factor, or a biologically active fragment thereof, or [the pseudo-ligand is] a nerve growth factor [pseudo-pseudo-ligand] pseudo-ligand that binds to the p75 nerve growth factor receptor.
34. (Amended) The method of Claim 33 wherein the pseudo-ligand is nerve growth factor, or a biologically active fragment thereof, wherein the fragment is a nerve growth factor peptide, or the pseudo-ligand is a nerve growth factor [pseudo-pseudo-ligand] pseudo-ligand that binds to the p75 nerve growth factor receptor.
38. (Amended) A method of Claim 37 wherein the pseudo-ligand is nerve growth factor, or a biologically active fragment thereof, or [the pseudo-ligand is] a nerve growth factor [pseudo-pseudo-ligand] pseudo-ligand that binds to the p75 nerve growth factor receptor.
42. (Amended) A method of Claim 41 wherein the pseudo-ligand is nerve growth factor, or a biologically active fragment thereof, or [the pseudo-ligand is] a nerve growth factor [pseudo-pseudo-ligand] pseudo-ligand that binds to the p75 nerve growth factor receptor.

46. (Amended) The method of Claim 45 wherein the pseudo-ligand is nerve growth factor, or a biologically active fragment thereof, or [the pseudo-ligand is] a nerve growth factor [pseudo-pseudo-ligand] pseudo-ligand that binds to the p75 nerve growth factor receptor.
49. (Amended) A method of treating a male with male pattern baldness, [comprising maintaining hair growth in the male] comprising inhibiting p75 nerve growth factor receptor-mediated apoptosis in keratinocytes by contacting the [keratinocyte] keratinocytes in the male with a pseudo-ligand, in an amount sufficient to inhibit apoptosis, that binds to a keratinocyte p75 nerve growth factor receptor, thereby inhibiting apoptosis, and maintaining hair growth.
50. (Amended) The method of Claim 49 wherein the pseudo-ligand is nerve growth factor, or a biologically active fragment thereof, or [the pseudo-ligand is] a nerve growth factor [pseudo-pseudo-ligand] pseudo-ligand that binds to the p75 nerve growth factor receptor.